Non-glycosylated SARS-CoV-2 RBD elicited a robust neutralizing antibody response in mice

2022/05/06 by Qian Ke, Peng Sun, Tiantian Wang +4 · 7 citations
Medicine · Agricultural and Biological Sciences · #SARS-CoV-2 and COVID-19 Research #Animal Virus Infections Studies #Viral gastroenteritis research and epidemiology

paper · doi:10.1016/j.jim.2022.113279

Citations

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Cited by

• Functional Expression of the Recombinant Spike Receptor Binding Domain of SARS-CoV-2 Omicron in the Periplasm of Escherichia coli . [europepmc]
• Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants. [europepmc]
• Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants. [europepmc]
• In vitro immune evaluation of adenoviral vector-based platform for infectious diseases. [europepmc]
• A protein vaccine of RBD integrated with immune evasion mutation shows broad protection against SARS-CoV-2. [europepmc]
• Protein Expression Platforms and the Challenges of Viral Antigen Production. [europepmc]
• Development of an in vitro method to assess the immunogenicity of biologics in the prevention of infectious diseases. [europepmc]